Impact of HIV-1 group O genetic diversity on genotypic resistance interpretation by algorithms designed for HIV-1 group M

Journal of Acquired Immune Deficiency Syndromes

Volumn 56, Issue 2, 2011, Pages 139-145

  Depatureaux, Agnès ^a,b   Charpentier, Charlotte ^a   Leoz, Marie ^a   Unal, Guillemette ^a   Damond, Florence ^c   Kfutwah, Anfunbom ^d   Vessière, Aurélia ^a,d   Simon, François ^e   Plantier, Jean Christophe ^a,d  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE ROUEN   (France)

^c BICHAT HOSPITAL   (France)

^d CENTRE PASTEUR DU CAMEROUN   (Cameroon)

^e SAINT LOUIS HOSPITAL   (France)

Author keywords

genotypic resistance; HIV 1 group O; natural polymorphism; resistance interpretation algorithms

Indexed keywords

ABACAVIR; ATAZANAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; GLYCOPROTEIN GP 41; INDINAVIR; INTEGRASE; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RITONAVIR PLUS TIPRANAVIR; RNA DIRECTED DNA POLYMERASE; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE;

ADULT; AGED; ALGORITHM; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; FOLLOW UP; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC RESISTANCE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; TREATMENT RESPONSE; VIRAL GENETICS; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE;

ALGORITHMS; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; GENETIC VARIATION; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION, MISSENSE; SEQUENCE ANALYSIS, DNA;

EID: 78751606408     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318201a904     Document Type: Article

References (33)

1. Ayouba A, Mauclere P, Martin PM, et al. HIV-1 group O infection in Cameroon, 1986 to 1998. Emerg Infect Dis. 2001;7:466-467.
2. Vessiere A, Rousset D, Kfutwah A, et al. Diagnosis and monitoring of HIV-1 group O-infected patients in Cameroun. J Acquir Immune Defic Syndr. 2010;53:107-110.
3. Agut H, Candotti D, Rabanel B, et al. Isolation of atypical HIV-1-related retrovirus from AIDS patient. Lancet. 1992;340:681-682.
4. Barin F, Cazein F, Lot F, et al. Prevalence of HIV-2 and HIV-1 group O infections among new HIV diagnoses in France: 2003-2006. AIDS. 2007; 21:2351-2353.
5. Roques P, Robertson DL, Souquiere S, et al. Phylogenetic analysis of 49 newly derived HIV-1 group O strains: high viral diversity but no group M-like subtype structure. Virology. 2002;302:259-273.
6. Archer J, Robertson DL. Understanding the diversification of HIV-1 groups M and O. AIDS. 2007;21:1693-1700.
7. Plantier JC, Djemai M, Lemee V et al. Census and analysis of persistent false-negative results in serological diagnosis of human immunodeficiency virus type 1 group O infections. J Clin Microbiol. 2009;47:2906-2911.
8. Gueudin M, Plantier JC, Lemee V et al. Evaluation of the Roche Cobas TaqMan and Abbott RealTime extraction-quantification systems for HIV-1 subtypes. J Acquir Immune Defic Syndr. 2007;44:500-505.
9. Gueudin M, Lemee V, Ferre V, et al. Virologic diagnosis and follow-up of children born to mothers infected by HIV-1 group O. J Acquir Immune Defic Syndr. 2004;36:639-641.
10. Delaugerre C, Merzoug M, Plantier JC, et al. Evaluation of extraction-quantification systems COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 test, version 2.0 vs M 2000SP/Abbott RealTime® HIV-1 in HIV-1 group M subtypes B and non-B, group O, and group P samples. Presented at: 17th Conference on Retroviruses and Opportunistic Infections; February 16-19, 2010; San Francisco, CA. Abstract 940.
11. de Baar MP, Janssens W, de Ronde A, et al. Natural residues versus antiretroviral drug-selected mutations in HIV type 1 group O reverse transcriptase and protease related to virological drug failure in vivo. AIDS Res Hum Retroviruses. 2000;16:1385-1394.
12. Rodes B, De Mendoza C, Rodgers M, et al. Treatment response and drug resistance in patients infected with HIV type 1 group O viruses. AIDS Res Hum Retroviruses. 2005;21:602-607.
13. Quiñones-Mateu ME, Albright JL, Mas A, et al. Analysis of pol gene heterogeneity, viral quasispecies, and drug resistance in individuals infected with group O strains of human immunodeficiency virus type 1. J Virol. 1998;72:9002-9015.
14. Descamps D, Collin G, Letourneur F, et al. Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses. J Virol. 1997;71:8893-8898.
15. Tuaillon E, Gueudin M, Lemée V, et al. Phenotypic susceptibility to nonnucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups. J Acquir Immune Defic Syndr. 2004;37: 1543-1549.
16. Chinnadurai R, Münch J, Dittmar MT, et al. Inhibition of HIV-1 group M and O isolates by fusion inhibitors. AIDS. 2005;19:1919-1922.
17. Poveda E, Barreiro P, Rodés B, et al. Enfuvirtide is active against HIV type 1 group O. AIDS Res Hum Retroviruses. 2005;21:583-585.
18. Depatureaux A, Charpentier C, Collin G, et al. Baseline genotypic and phenotypic susceptibilityof HIV-1 group O to enfuvirtide. Antimicrob Agents Chemother. 2010;54:4016-4019.
19. Leoz M, Depatureaux A, Vessière A, et al. Integrase polymorphism and HIV-1 group O diversity. AIDS. 2008;22:1239-1243.
20. Briz V, Garrido C, Poveda E, et al. Raltegravir and etravirine are active against HIV type 1 group O. AIDS Res Hum Retroviruses. 2009;25: 225-227.
21. Vergne L, Peeters M, Mpoudi-Ngole E, et al. Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol. 2000;38: 3919-3925.
22. Quiñones-Mateu ME, Soriano V, Domingo E, et al. Characterization of the reverse transcriptase of a human immunodeficiency virus type 1 group O isolate. Virology. 1997;236:364-373.
23. Depatureaux A, Leoz M, Vessière A, et al. Natural presence of resistance mutation Y181C in HIV-1 group O variants is clade-dependent. Antivir Ther. 2009;14(Suppl 1):A93.
24. Kantor R, Katzenstein DA, Efron B, et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med. 2005;2:e112.
25. Colson P, Henry M, Tourres C, et al. Polymorphism and drug-selected mutations in the protease gene of human immunodeficiency virus type 2 from patients living in Southern France. J Clin Microbiol. 2004;42: 570-577.
26. Ntemgwa M, Brenner BG, Oliveira M, et al. Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors. Antimicrob Agents Chemother. 2007;51:604-610.
27. Desbois D, Roquebert B, Peytavin G, et al. In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors. Antimicrob Agents Chemother. 2008;52: 1545-1548.
28. Parkin NT, Schapiro JM. Antiretroviral drug resistance in non-subtype B HIV-1, HIV-2 and SIV. Antivir Ther. 2004;9:3-12.
29. Witvrouw M, Pannecouque C, Switzer WM, et al. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther. 2004;9:57-65.
30. Deshpande A, Jauvin V, Magnin N, et al. Resistance mutations in subtype C HIV type 1 isolates from Indian patients of Mumbai receiving NRTIs plus NNRTIs and experiencing a treatment failure: resistance to AR. AIDS Res Hum Retroviruses. 2007;23:335-340.
31. Marcelin AG, Masquelier B, Descamps D, et al. Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients. Antimicrob Agents Chemother. 2008;52:3237-3243.
32. Chen Z, Li Y, Schock HB, et al. Three-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trials. J Biol Chem. 1995;270:21433-21436.
33. Liu L, May S, Richman DD, et al. Comparison of algorithms that interpret genotypic HIV-1 drug resistance to determine the prevalence of transmitted drug resistance. AIDS. 2008;22:835-839.